Julia Riedl

List of Publications by Year
in descending order

17	774	759233 12	940533 16
papers	citations	h-index	g-index

17	17	17	1275
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. Lancet Haematology,the, 2018, 5, e289-e298.	4.6	219
2	Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism. Blood, 2017, 129, 1831-1839.	1.4	164
3	Red Cell Distribution Width and Other Red Blood Cell Parameters in Patients with Cancer: Association with Risk of Venous Thromboembolism and Mortality. PLoS ONE, 2014, 9, e111440.	2.5	64
4	Association Between Decreased Serum Albumin With Risk of Venous Thromboembolism and Mortality in Cancer Patients. Oncologist, 2016, 21, 252-257.	3.7	63
5	Venous Thromboembolism in Brain Tumors: Risk Factors, Molecular Mechanisms, and Clinical Challenges. Seminars in Thrombosis and Hemostasis, 2019, 45, 334-341.	2.7	44
6	Association of platelet activation markers with cancer-associated venous thromboembolism. Platelets, 2016, 27, 80-85.	2.3	42
7	The role of podoplanin in cancer-associated thrombosis. Thrombosis Research, 2018, 164, S34-S39.	1.7	42
8	Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal Dâ€Dimer analysis: A prospective study. Journal of Thrombosis and Haemostasis, 2020, 18, 1348-1356.	3.8	34
9	Alterations of blood coagulation in controlled human malaria infection. Malaria Journal, 2016, 15, 15.	2.3	26
10	Association of complete blood count parameters, dâ€dimer, and soluble Pâ€selectin with risk of arterial thromboembolism in patients with cancer. Journal of Thrombosis and Haemostasis, 2019, 17, 1335-1344.	3.8	25
11	A new measure for in vivo thrombin activity in comparison with in vitro thrombin generation potential in patients with hyper- and hypocoagulability. Clinical and Experimental Medicine, 2017, 17, 251-256.	3.6	16
12	Low Systemic Levels of Chemokine C-C Motif Ligand 3 (CCL3) are Associated with a High Risk of Venous Thromboembolism in Patients with Glioma. Cancers, 2019, 11, 2020.	3.7	13
13	Platelets and hemophilia: A review of the literature. Thrombosis Research, 2017, 155, 131-139.	1.7	11
14	Direct oral anticoagulants: now also for prevention and treatment of cancer-associated venous thromboembolism?. Hematology American Society of Hematology Education Program, 2017, 2017, 136-143.	2.5	4
15	Association of programmed cell death ligand 1 and circulating lymphocytes with risk of venous thromboembolism in patients with glioma. ESMO Open, 2020, 5, e000647.	4.5	4
16	Red Cell Distribution Width and Other Red Blood Cell Parameters in Patients with Cancer: Association with Risk of Venous Thromboembolism and Mortality. Blood, 2014, 124, 2859-2859.	1.4	3
17	Synergism between pyronaridine and retinol in Plasmodium vivax in vitro. Wiener Klinische Wochenschrift, 2010, 122, 66-70.	1.9	0